comparemela.com

Latest Breaking News On - Concert pharmaceuticals inc - Page 2 : comparemela.com

Axinn IP Update: Federal Circuit Applies Lead Compound Analysis and Confirms Obviousness of Deuterated Derivatives of Ruxolitinib | Axinn, Veltrop & Harkrider LLP

On August 22, 2023, the Federal Circuit affirmed an IPR Final Written Decision holding claims to deuterated derivatives of ruxolitinib unpatentable as obvious and rejected the.

India s Sun Pharma Posts Near-30% Rise In Q4 Profit On Lower Input Costs

India s Sun Pharma posts near-30% rise in Q4 profit on lower input costs

BENGALURU -Sun Pharmaceutical Industries Ltd, India s largest drugmaker by revenue, on Friday reported a 29.6% rise in fourth-quarter profit, as it benefited from lower expenses and higher sales of. | May 26, 2023

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.